Approvals of Pharmaceutical Drugs in China in the Post–Drug Registration Regulation II Era

Abstract

Objective:

To delineate the impact of the revised Drug Registration Regulation (DRR II) issued in 2007 on drug approval in China and reveal the change in approval situations for new drugs and generic drugs in the post–DRR II era (2007-2011).

Methods:

Data of drug approvals were collected from the database of the China Food and Drug Administration (CFDA) and were analyzed by introducing 3 ratio indicators and utilizing statistical analysis tools.

Results:

In the post–DRR II era, the drug approvals showed a general trend of the following: (1) a statistically significant rise in both the absolute number and proportion of new drugs, (2) a nonsignificant change for drugs in new dosage forms, and (3) a statistically significant drop in both the absolute number and proportion of generic drugs. On the other hand, Class 1 (new chemical entities) drugs accounted for an extremely small proportion in new drugs. Except for the rise in gastrointestinal and cardiovascular new drugs, no significant changes were found in other therapeutic categories.

Conclusions:

Thanks to the DRR II, the aberration in Chinese drug registration has been terminated. Approvals for new drugs and high-quality generics are the main trends. Because of the severe paucity of Class 1 drugs, innovation and collaboration will be the main 2 themes for the Chinese pharmaceutical industry as well as the upcoming version of the DRR III in the near future.

Keywords

chemical drug registration evaluation regulation approvals

Get full access to this article

View all access options for this article.

References

China Food and Drug Administration. Drug Administration Law of People’s Republic of China [in Chinese]. Available at: http://www.sda.gov.cn/WS01/CL0064/23396.html. Accessed July 23, 2012.

Kaitin

Deng

. The regulation and approval of new drugs in China. Drug Inf J. 2004;38:29–39.

Shao

The Reformation and Development of Supervision of Drugs and Foods in China. Beijing, China: Medicine Science and Technology Press of China; 2009:79–89.

Yin

. Regulations and procedures for new drug evaluation and approval in China. Hum Gene Ther. 2006;17(10):970–974.

China Food and Drug Administration. Drug registration regulation of People’s Republic of China [in Chinese]. Available at: http://www.sfda.gov.cn/WS01/CL0053/24529.html. Accessed July 23, 2012.

Fang

. Statistical Methods for Biomedical Research. Beijing: Higher Education Press; 2007.

China Food and Drug Administration. Database of CFDA [in Chinese]. Available at: http://app1.sfda.gov.cn/datasearch/face3/dir.html. Accessed July 23, 2012.

Chenoweth

. Is more really less in China’s new drug approvals? Drug Discov Today. 2005;10(17):1140–1142.

Kaitin

DiMasi

. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89(2):183–188.

10.

Berndt

Gottschalk

Philipson

Strobeck

. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov. 2005;4(7):545–554.

11.

Xinhua News Agency. National 12th Five Plan [in Chinese]. Available at: http://www.gov.cn/2011lh/content_1825838.htm. Accessed July 23, 2012.

12.

China Food and Drug Administration. Administrative regulations for technology transfer registration of drugs [in Chinese]. Available at: http://www.sda.gov.cn/WS01/CL0055/40893.html. Accessed July 23, 2012.

13.

China Food and Drug Administration. To deepen the revolution of drug evaluation and approval and to further encourage drug innovation [in Chinese]. Available at: http://www.gov.cn/gzdt/2013-02/26/content_2340604.htm. Accessed March 2013.

14.

Munos

. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959–968.

15.

Mao

Zheng

. Encouraging an environment for pharmaceutical R&D in China. J Pharm Innov. 2009;4(3):152–154.